PCR invest over $2.8m in better future for men

We couldn't have done it without you

Thanks to your support, PCR will be supporting 175% more research next year than last year.

This major boost for prostate cancer research will make a huge difference to men like me, and men who will not be so lucky and will be diagnosed with aggressive cancer. Having worked with the charity on the Stephen and Martin Appeal just last year I am proud to see them doing such wonderful things this year.

Stephen Fry

Meeting the Challenge

Prostate cancer is the second most common cancer killer in men, killing 93 men a day in the US. If breakthroughs are not made, it could kill over 120 men a day by 2035. Even though the number of men diagnosed with prostate cancer in the US has shot up since the early 1990s, money being spent on prostate cancer research is decreasing. Federal funding for prostate cancer research has accounted for, on average, only five percent of our nation’s annual cancer research budget. However, prostate cancer is responsible for about 19 percent of all cancer cases and eight percent of cancer deaths in men. Our new grants will significantly increase the amount of money spent on prostate cancer research. Between these new projects and our existing projects, we’ve committed to spending at least $5 million on prostate cancer research in the next few years.

We want to say A MASSIVE THANK YOU to our marathon runners, mountain climbers, generous givers, Racers for Science, and all of our #TeamPCR superstars who’ve made this possible.

Tailoring Treatments

In 2019, we don’t know enough about prostate cancer to predict how aggressive a man’s prostate cancer will be, what treatment will work best for him, or even if he needs to be treated at all.

We believe that if there were more treatment options, and we understood cancer better, men could receive treatments which were more tailored to the cancer they have and less “one size fits all.” We also need to find treatments that are better at attacking cancer, with less side effects.

As a man with prostate cancer, it was a privilege to be involved in the selection process for the funding of new projects. For men like me and for our nearest and dearest, it is essential that scientists and clinicians are able to carry out the essential work of finding new ways to treat this potentially devastating disease.

Dr David Matheson
PCR Patient Panel Member

And the awards went to...

Our new projects are tackling the problem of how to personalize treatment in different ways. Following an incredibly tough selection process, including a detailed application form, review by prostate cancer patients, a number of scientific experts, and character references, we’re delighted to announce we’re funding seven new research teams in six locations.

Three of our new projects

In Cambridge, Dr Jorge de la Rosa is solving the riddle of how complex genetic networks promote cancer.

In OxfordProfessor Bart Cornelissen is looking for ways to improve radiotherapy.

In London, Professor Gert Attard at UCL is investigating genetic changes, using DNA from men who took part in the STAMPEDE clinical trial.


Find out more:

"We are delighted to have announced $2.8m of investment into new research today. There is no shortage of talented scientists exploring innovative methods to discover better treatments and diagnostics. However, research into prostate cancer in the US continues to be underfunded. To address this major issue, there is an urgent need to work together with Government, commercial partners, private individuals and other charities in order to fund more research and give scientists the support they need to make the necessary breakthroughs."

Matthew Ellis

Let's keep working together to turn hope into reality

Press enter or esc to cancel